J.J. Body

1.8k total citations
47 papers, 1.4k citations indexed

About

J.J. Body is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Orthopedics and Sports Medicine. According to data from OpenAlex, J.J. Body has authored 47 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 16 papers in Radiology, Nuclear Medicine and Imaging and 12 papers in Orthopedics and Sports Medicine. Recurrent topics in J.J. Body's work include Bone health and treatments (39 papers), Radiopharmaceutical Chemistry and Applications (15 papers) and Cancer Diagnosis and Treatment (10 papers). J.J. Body is often cited by papers focused on Bone health and treatments (39 papers), Radiopharmaceutical Chemistry and Applications (15 papers) and Cancer Diagnosis and Treatment (10 papers). J.J. Body collaborates with scholars based in Belgium, France and United States. J.J. Body's co-authors include Pierre D. Delmas, Alexander Paterson, Ingo Diel, John А. Kanis, P. Burckhardt, Gregory R. Mundy, R.D. Rubens, Reiner Bartl, Robert A. Kyle and H. Fleisch and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer Research.

In The Last Decade

J.J. Body

47 papers receiving 1.3k citations

Peers

J.J. Body
Howard Yeh United States
Blair Egerdie Canada
G. Gorzegno Italy
Bijvoet Ol Netherlands
Allan Lipton United States
D Ethgen Belgium
S.H. Ralston United Kingdom
Guillermo Alonso Spain
J. Walls United Kingdom
L.V.A.M. Beex Netherlands
Howard Yeh United States
J.J. Body
Citations per year, relative to J.J. Body J.J. Body (= 1×) peers Howard Yeh

Countries citing papers authored by J.J. Body

Since Specialization
Citations

This map shows the geographic impact of J.J. Body's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.J. Body with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.J. Body more than expected).

Fields of papers citing papers by J.J. Body

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.J. Body. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.J. Body. The network helps show where J.J. Body may publish in the future.

Co-authorship network of co-authors of J.J. Body

This figure shows the co-authorship network connecting the top 25 collaborators of J.J. Body. A scholar is included among the top collaborators of J.J. Body based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.J. Body. J.J. Body is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schwarz, Peter, J.J. Body, Cáp J, et al.. (2014). The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. European Journal of Endocrinology. 171(6). 727–735. 44 indexed citations
2.
Rizzoli, René, J.J. Body, Maria Luisa Brandi, et al.. (2013). Cancer-associated bone disease. Osteoporosis International. 24(12). 2929–2953. 108 indexed citations
3.
Beuselinck, Benoit, Pascal Wolter, Alexandra Karadimou, et al.. (2012). Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. British Journal of Cancer. 107(10). 1665–1671. 86 indexed citations
4.
Garcia, C., Lieveke Ameye, Bruno Vanderlinden, et al.. (2010). Heterogeneity of Metabolic Response to Systemic Therapy in Metastatic Breast Cancer Patients. Clinical Oncology. 22(10). 818–827. 49 indexed citations
5.
Stopeck, Alison, Miguel Martín, Diana Ritchie, et al.. (2010). Abstract P6-14-01: Effect of Denosumab Versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone Metastases: Results from the Extended Blinded Treatment Phase. Cancer Research. 70(24_Supplement). P6–14. 12 indexed citations
6.
Stopeck, Alison, J.J. Body, Yasuyuki Fujiwara, et al.. (2009). 2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. European Journal of Cancer Supplements. 7(3). 2–3. 63 indexed citations
7.
Bergmann, P., J.J. Body, Steven Boonen, et al.. (2008). Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. International Journal of Clinical Practice. 63(1). 19–26. 114 indexed citations
8.
Body, J.J., Pierre Bergmann, S. Boonen, et al.. (2007). Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporosis International. 18(11). 1439–1450. 82 indexed citations
9.
Devogelaer, Jean‐Pierre, P. Burckhardt, P Meunier, et al.. (2006). Zoledronic acid safety and efficacy over 5 years in post-menopausal osteoporosis. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
10.
Bergström, B., M. Lichinitser, & J.J. Body. (2006). Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: Evidence from comparative phase III trials. Bone. 38(3). 68–69. 5 indexed citations
11.
Journé, Fabrice, Carole Chaboteaux, J.C. Dumon, et al.. (2004). Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells. British Journal of Cancer. 91(9). 1703–1710. 20 indexed citations
12.
Journé, Fabrice, J.C. Dumon, Naı̈ma Kheddoumi, et al.. (2004). Extracellular calcium downregulates estrogen receptor alpha and increases its transcriptional activity through calcium-sensing receptor in breast cancer cells. Bone. 35(2). 479–488. 43 indexed citations
13.
Cloos, Paul A., Christian Fledelius, Stephan Christgau, et al.. (2003). Investigation of Bone Disease Using Isomerized and Racemized Fragments of Type I Collagen. Calcified Tissue International. 72(1). 8–17. 27 indexed citations
14.
Fromigué, Olivia, Naı̈ma Kheddoumi, & J.J. Body. (2003). Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. British Journal of Cancer. 89(1). 178–184. 42 indexed citations
15.
Rizzoli, R., D. Thiébaud, Nigel Bundred, et al.. (1999). Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy. The Journal of Clinical Endocrinology & Metabolism. 84(10). 3545–3550. 32 indexed citations
16.
Body, J.J., Reiner Bartl, P. Burckhardt, et al.. (1998). Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.. Journal of Clinical Oncology. 16(12). 3890–3899. 274 indexed citations
17.
Kaufman, Jean‐Marc, J.-P. Devogelaer, F. Raeman, et al.. (1997). Prevention and treatment of postmenopausal osteoporosis national consensus of the “belgian bone club”, November 1996. Clinical Rheumatology. 16(4). 343–345. 10 indexed citations
18.
Body, J.J., et al.. (1997). Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. British Journal of Cancer. 75(3). 408–412. 43 indexed citations
19.
Dumon, J.C., et al.. (1996). Technical and clinical validation of a new immunoradiometric assay for human osteocalcin. European Journal of Endocrinology. 135(2). 231–237. 20 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Howard Yeh Breakdown of academic impact, for papers by Blair Egerdie Breakdown of academic impact, for papers by G. Gorzegno Breakdown of academic impact, for papers by Bijvoet Ol Breakdown of academic impact, for papers by Allan Lipton Breakdown of academic impact, for papers by D Ethgen Breakdown of academic impact, for papers by S.H. Ralston Breakdown of academic impact, for papers by Guillermo Alonso Breakdown of academic impact, for papers by J. Walls Breakdown of academic impact, for papers by L.V.A.M. Beex
Rankless by CCL
2026